Provided is an isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), in which the CAR includes a single chain antibody or single chain antibody fragment, a costimulatory domain, a primary intracellular signaling domain. The single chain antibody or single chain antibody fragment includes a murine anti-CD19 binding domain, wherein the murine anti-CD19 binding domain includes a heavy chain variable (VH) region comprising a heavy chain complementarity determining region (CDR H1), a CDR H2, and a CDR H3; and a light chain variable (VL) region comprising a light chain complementarity determining region 1 (CDR L1), a CDR L2, and a CDR L3. The costimulatory domain includes 4-1BB, and the primary intracellular signaling domain includes a native intracellular signaling domain of CD3 zeta.

The present application relates to an antigen-binding polypeptide that specifically binds to B7H3, comprising at least one complementarity-determining region (CDR) of an antibody heavy chain variable region (VH), wherein the VH comprises an amino acid sequence set forth in SEQ ID NO: 25. The present application further relates to a chimeric antigen receptor comprising the antigen-binding polypeptide and a universal CAR-T cell comprising the chimeric antigen receptor. The CAR-T cell recognizes a surface antigen of a tumor cell and knocks out TCR and HLA-A genes expressed by the cell at the same time, so that the immune rejection caused by an allogeneic CAR-T therapy is reduced, the survival time of the cell is prolonged, and the anti-tumor effect is improved.

The present invention provides cellular tags including an extracellular region, a transmembrane region, and an optional intracellular region. The extracellular region comprises an IL5 receptor alpha (IL5Ra) sequence linked to a transmembrane domain, and the recombinant polypeptide cannot function in signal transduction. The cellular tags can be operably linked to transgenes. The expression of the cellular tag allows identification, detection, selection, and ablation of cells expressing the transgene and the cellular tag. In some embodiments the genetically modified host cell comprises a transgene comprising a polynucleotide coding for a chimeric antigen receptor comprising a ligand binding domain, and a polynucleotide coding for a cellular tag. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.

CAR Tregs and Tregs are provided which are both conversion-resistant and condition-resistant. The Treg cells are engineered such that they are deficient in or substantially devoid of a cell-surface marker or antigen.

Described herein are antigen binding proteins with specificity to Melanoma-Associated Antigen A4 (MAGE-A4) peptide-MHC (pMHC). Also described are multispecific antigen binding proteins comprising an antigen binding domain with specificity to CD3, and at least one MAGE-A4 pMHC antigen binding domain. Methods of treating cancer with the same are also described.

The present invention provides an antibody that binds to a linker in a new style of binding. More specifically, the present invention provides an antibody that binds to the linking part between a first region and a linker and the linking part between a linker and a second region in an scFv structure.

The invention relates to an artificial T cell receptor, wherein an antigen binding domain of the artificial T cell receptor specifically binds a complement pathway protein, nucleic acids encoding such artificial T cell receptors and cells engineered to express such nucleic acids. The invention also relates to targeting polypeptides comprising an extracellular ligand binding domain and an intracellular domain comprising a transcription factor, and wherein the transcription factor is configured to be released upon binding of the ligand binding domain by a ligand. The invention also relates to cells engineered to express the artificial T cell receptor and the targeting polypeptide, particularly where expression of the artificial T cell receptor is operatively linked to binding of the ligand binding domain. The cells of the invention are useful in medicine, particularly in the treatment of inflammatory conditions.